Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Sees Significant Decrease in Short Interest

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the target of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 152,000 shares, a decrease of 14.2% from the May 31st total of 177,100 shares. Currently, 3.3% of the shares of the company are sold short. Based on an average trading volume of 207,800 shares, the short-interest ratio is currently 0.7 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Phio Pharmaceuticals in a research report on Tuesday, May 14th.

Phio Pharmaceuticals Price Performance

Shares of NASDAQ PHIO traded down $0.02 during midday trading on Monday, hitting $0.67. 21,957 shares of the company’s stock were exchanged, compared to its average volume of 265,800. Phio Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $3.23. The firm has a market cap of $3.08 million, a P/E ratio of -0.21 and a beta of 1.45. The stock’s 50 day moving average price is $0.74 and its 200-day moving average price is $0.74.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.47) earnings per share (EPS) for the quarter. On average, analysts expect that Phio Pharmaceuticals will post -1.82 EPS for the current fiscal year.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.